---
title: Acid Production in Dental Plaque After Exposure to Probiotic Bacteria
nct_id: NCT01700712
overall_status: COMPLETED
phase: NA
sponsor: University of Copenhagen
study_type: INTERVENTIONAL
primary_condition: Caries
countries: Denmark
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT01700712.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT01700712"
ct_last_update_post_date: 2012-10-04
last_seen_at: "2026-05-12T06:29:43.885Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Acid Production in Dental Plaque After Exposure to Probiotic Bacteria

**NCT ID:** [NCT01700712](https://clinicaltrials.gov/study/NCT01700712)

## Key Facts

- **Status:** COMPLETED
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 18
- **Lead Sponsor:** University of Copenhagen
- **Collaborators:** BioGaia AB, Calcin foundation, Denmark
- **Conditions:** Caries
- **Start Date:** 2010-12
- **Completion Date:** 2011-10
- **CT.gov Last Update:** 2012-10-04

## Brief Summary

The increasing interest in probiotic lactobacilli in health maintenance has raised the question of potential risks. One possible side effect could be an increased acidogenicity in dental plaque. The aim of this study was to investigate the effect of probiotic lactobacilli on plaque lactic acid (LA) production in vitro and in vivo.

Methods. subjects (n=18) were given lozenges with probiotic lactobacilli (L. reuteri DSM 17938 and ATCC PTA 5289) or placebo for two weeks in a double-blinded, randomized cross-over trial. The concentration of LA in supragingival plaque samples was determined at baseline and after 2 weeks. Salivary counts of mutans streptococci (MS) and lactobacilli were estimated with chair-side methods.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

* moderate to high counts of salivary mutans streptococci (\>104 CFU) as estimated with the Dentocult SM chair-side test,
* no visible open caries lesions or periodontal disease,

Exclusion Criteria:

* smokers,
* ingestion of probiotic bacteria within the last two months,
* ingestion of antibiotics within the last two months
```

## Arms

- **L. reuteri (DSM 17938 and ATCC PTA 5289; 1x108 CFU** (ACTIVE_COMPARATOR) — 2 tablets a day for 2 weeks
- **Sugar pill** (PLACEBO_COMPARATOR) — 2 tablets a day for 2 weeks

## Interventions

- **Probiotic Lactobacilli reuteri** (DIETARY_SUPPLEMENT)
- **Placebo** (DIETARY_SUPPLEMENT)

## Primary Outcomes

- **Acid production in plaque after exposure to probiotic bacteria** _(time frame: 2 weeks)_

## Secondary Outcomes

- **Acid producton in plaque after in vitro exposure to probiotic bacteria** _(time frame: 1 hour)_

## Locations (1)

- University of Copenhagen, Copenhagen, Denmark

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.university of copenhagen|copenhagen||denmark` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT01700712.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT01700712*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*